• Axsome Therapeutics CEO Herriot Tabuteau sold 49,666 shares on July 1 at an average price of $240.25.
• He also acquired 49,666 shares at $4.95 through an option exercise on the same day.
• Directly held stake ended at 7,229 shares.
• He reported 7,344,500 shares held indirectly through an entity he controls.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-292985), on July 01, 2026, and is solely responsible for the information contained therein.